Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
CXCR6 by increasing retention of memory CD8+ T cells in the ovarian tumor microenvironment promotes immunosurveillance and control of ovarian cancer.
Muthuswamy R, McGray AR, Battaglia S, He W, Miliotto A, Eppolito C, Matsuzaki J, Takemasa T, Koya R, Chodon T, Lichty BD, Shrikant P, Odunsi K. Muthuswamy R, et al. Among authors: miliotto a. J Immunother Cancer. 2021 Oct;9(10):e003329. doi: 10.1136/jitc-2021-003329. J Immunother Cancer. 2021. PMID: 34607898 Free PMC article.
A prime/boost vaccine platform efficiently identifies CD27 agonism and depletion of myeloid-derived suppressor cells as therapies that rationally combine with checkpoint blockade in ovarian cancer.
McGray AJR, Eppolito C, Miliotto A, Singel KL, Stephenson K, Lugade A, Segal BH, Keler T, Webster G, Lichty B, Kozbor D, Odunsi K. McGray AJR, et al. Among authors: miliotto a. Cancer Immunol Immunother. 2021 Dec;70(12):3451-3460. doi: 10.1007/s00262-021-02936-1. Epub 2021 Apr 20. Cancer Immunol Immunother. 2021. PMID: 33880648 Free PMC article.
Efficient identification of neoantigen-specific T-cell responses in advanced human ovarian cancer.
Liu S, Matsuzaki J, Wei L, Tsuji T, Battaglia S, Hu Q, Cortes E, Wong L, Yan L, Long M, Miliotto A, Bateman NW, Lele SB, Chodon T, Koya RC, Yao S, Zhu Q, Conrads TP, Wang J, Maxwell GL, Lugade AA, Odunsi K. Liu S, et al. Among authors: miliotto a. J Immunother Cancer. 2019 Jun 20;7(1):156. doi: 10.1186/s40425-019-0629-6. J Immunother Cancer. 2019. PMID: 31221207 Free PMC article.
Oncolytic Maraba virus armed with tumor antigen boosts vaccine priming and reveals diverse therapeutic response patterns when combined with checkpoint blockade in ovarian cancer.
McGray AJR, Huang RY, Battaglia S, Eppolito C, Miliotto A, Stephenson KB, Lugade AA, Webster G, Lichty BD, Seshadri M, Kozbor D, Odunsi K. McGray AJR, et al. Among authors: miliotto a. J Immunother Cancer. 2019 Jul 17;7(1):189. doi: 10.1186/s40425-019-0641-x. J Immunother Cancer. 2019. PMID: 31315674 Free PMC article.
Clonality and antigen-specific responses shape the prognostic effects of tumor-infiltrating T cells in ovarian cancer.
Tsuji T, Eng KH, Matsuzaki J, Battaglia S, Szender JB, Miliotto A, Gnjatic S, Bshara W, Morrison CD, Lele S, Emerson RO, Wang J, Liu S, Robins H, Lugade AA, Odunsi K. Tsuji T, et al. Among authors: miliotto a. Oncotarget. 2020 Jul 7;11(27):2669-2683. doi: 10.18632/oncotarget.27666. eCollection 2020 Jul 7. Oncotarget. 2020. PMID: 32676168 Free PMC article.
Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer.
Odunsi K, Matsuzaki J, James SR, Mhawech-Fauceglia P, Tsuji T, Miller A, Zhang W, Akers SN, Griffiths EA, Miliotto A, Beck A, Batt CA, Ritter G, Lele S, Gnjatic S, Karpf AR. Odunsi K, et al. Among authors: miliotto a. Cancer Immunol Res. 2014 Jan;2(1):37-49. doi: 10.1158/2326-6066.CIR-13-0126. Cancer Immunol Res. 2014. PMID: 24535937 Free PMC article. Clinical Trial.
19 results